Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Share this content:

Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)

Contact
Click here for all study locations and contact info

Investigators
Edward M. Messing, MD, FACS     
James P. Wilmot Cancer Center

David P. Wood, MD     
University of Michigan Cancer Center

ClinicalTrials.gov Identifier
NCT00445601

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.